Abstract
This chapter focuses on potent antagonistic analogs of growth hormone-releasing hormone (GH-RH) in cancer. GHRH antagonists inhibit the growth, tumorigenicity, and metastases of a wide range of human experimental malignancies. GH-RH antagonists bind to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The presence of GH-RH ligand was demonstrated in various cancers, suggesting that GH-RH could be an autocrine growth factor. GH-RH antagonists inhibit the growth of various human cancer lines xenografted into nude mice, including breast cancers, prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, malignant gliomas, renal cell carcinomas, pancreatic cancers, colorectal carcinomas, and lymphomas. These effects of GHRH antagonists could be exerted in part indirectly through inhibition of the secretion of pituitary GH and the resulting reduction in the levels of hepatic IGF-I. However, the principal effect of GH-RH antagonists appears to be the direct suppression of action of the autocrine GHRH and the secretion of IGF-I and IGF-II in tumors, as well as expression of the genes encoding them. These direct effects of GHRH antagonists are exerted on GHRH receptors and their splice variants on tumors. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.
| Original language | English |
|---|---|
| Title of host publication | Handbook of Biologically Active Peptides |
| Publisher | Elsevier Inc. |
| Pages | 483-489 |
| Number of pages | 7 |
| ISBN (Print) | 9780123694423 |
| DOIs | |
| State | Published - Dec 1 2006 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer. / Varga, Jozsef L.; Schally, Andrew V.
Handbook of Biologically Active Peptides. Elsevier Inc., 2006. p. 483-489.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer
AU - Varga, Jozsef L.
AU - Schally, Andrew V
PY - 2006/12/1
Y1 - 2006/12/1
N2 - This chapter focuses on potent antagonistic analogs of growth hormone-releasing hormone (GH-RH) in cancer. GHRH antagonists inhibit the growth, tumorigenicity, and metastases of a wide range of human experimental malignancies. GH-RH antagonists bind to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The presence of GH-RH ligand was demonstrated in various cancers, suggesting that GH-RH could be an autocrine growth factor. GH-RH antagonists inhibit the growth of various human cancer lines xenografted into nude mice, including breast cancers, prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, malignant gliomas, renal cell carcinomas, pancreatic cancers, colorectal carcinomas, and lymphomas. These effects of GHRH antagonists could be exerted in part indirectly through inhibition of the secretion of pituitary GH and the resulting reduction in the levels of hepatic IGF-I. However, the principal effect of GH-RH antagonists appears to be the direct suppression of action of the autocrine GHRH and the secretion of IGF-I and IGF-II in tumors, as well as expression of the genes encoding them. These direct effects of GHRH antagonists are exerted on GHRH receptors and their splice variants on tumors. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.
AB - This chapter focuses on potent antagonistic analogs of growth hormone-releasing hormone (GH-RH) in cancer. GHRH antagonists inhibit the growth, tumorigenicity, and metastases of a wide range of human experimental malignancies. GH-RH antagonists bind to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The presence of GH-RH ligand was demonstrated in various cancers, suggesting that GH-RH could be an autocrine growth factor. GH-RH antagonists inhibit the growth of various human cancer lines xenografted into nude mice, including breast cancers, prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, malignant gliomas, renal cell carcinomas, pancreatic cancers, colorectal carcinomas, and lymphomas. These effects of GHRH antagonists could be exerted in part indirectly through inhibition of the secretion of pituitary GH and the resulting reduction in the levels of hepatic IGF-I. However, the principal effect of GH-RH antagonists appears to be the direct suppression of action of the autocrine GHRH and the secretion of IGF-I and IGF-II in tumors, as well as expression of the genes encoding them. These direct effects of GHRH antagonists are exerted on GHRH receptors and their splice variants on tumors. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.
UR - http://www.scopus.com/inward/record.url?scp=58149481977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149481977&partnerID=8YFLogxK
U2 - 10.1016/B978-012369442-3/50073-8
DO - 10.1016/B978-012369442-3/50073-8
M3 - Chapter
AN - SCOPUS:58149481977
SN - 9780123694423
SP - 483
EP - 489
BT - Handbook of Biologically Active Peptides
PB - Elsevier Inc.
ER -